

October 12, 2023



Poxel Announces its Participation at Upcoming Investor Conferences

LYON, France--(BUSINESS WIRE)-- Regulatory News:

[POXEL SA](#) (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced that it will participate at two upcoming investor conferences.

- **7th Annual H.C.Wainwright NASH Investor Conference – virtual conference**
Date: October 24, 2023

Thomas Kuhn, Chief Executive Officer, and Pascale Fouqueray, Executive Vice President, Clinical Development and Regulatory Affairs, will present the NASH related programs of Poxel during a dedicated virtual presentation, and will be available to investors for one-on-one virtual meetings.

- **Healthtech Innovation Days – Paris, France – in-person and virtual conference**
Date: October 24-25, 2023

Thomas Kuhn, Chief Executive Officer, and other members of the management of Poxel, will be available to investors for one-on-one in person and virtual meetings.

About NASH

Non-alcoholic steatohepatitis (NASH) is a metabolic disease with no clear disease origin that is quickly becoming a worldwide epidemic. It is characterized by the accumulation of fat in the liver causing inflammation and fibrosis. The disease can be silent for a long period of time, but once it accelerates, severe damage and liver cirrhosis can occur, which can significantly impact liver function or can even result in liver failure or liver cancer. Typical risk factors for NASH include obesity, elevated levels of blood lipids (such as cholesterol and triglycerides) and type 2 diabetes. Currently no curative or specific therapies are available.

About Poxel SA

Poxel is a **clinical stage biopharmaceutical company** developing **innovative treatments for chronic serious diseases with metabolic pathophysiology**, including **non-alcoholic steatohepatitis (NASH)** and rare disorders. For the treatment of NASH, **PXL065** (deuterium-stabilized *R*-pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of **PXL770**, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of

adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). **TWYMEEG**[®] (Imeglimin), Poxel's first-in-class product that targets mitochondrial dysfunction, is marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan, China, and eleven other Asian countries. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.

For more information, please visit: www.poxelpharma.com

All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. The Company does not endorse or is not otherwise responsible for the content of external hyperlinks referred to in this press release.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20231011367166/en/>

Investor relations / Media

Aurélie Bozza

Investor Relations & Corporate Communications Vice-president

aurelie.bozza@poxelpharma.com

+33 6 99 81 08 36

NewCap

Nicolas Fossiez, Aurélie Manavarere / Arthur Rouillé

poxel@newcap.eu

+33 1 44 71 94 94

Source: Poxel